Omnicell appointed Nnamdi Njoku as President, in addition to his role as Chief Operating Officer, effective July 1, 2026, as Randall A. Lipps stepped down as President while remaining CEO and Chairman.
| IndividualNnamdi NjokuRandall A. Lipps | RolePresident; Chief Operating OfficerChief Executive Officer; Chairman of the Board (former President) | Type of ChangeAppointed/PromotedStepped down from President role | Effective DateJuly 1, 2026June 30, 2026 (transition effective July 1, 2026) | ReasonTo shape and advance long-term growth strategy and scale global operations (per filing)Transitioned President duties to Mr. Njoku; will continue as CEO and Chairman | Replacement InfoN/APresident duties transferred to Nnamdi Njoku | Background DetailsFormer EVP & COO of Omnicell (Oct 2024–Jun 2026); prior leadership roles at Zimmer Biomet, Medtronic, UnitedHealth, Deloitte; BA (Univ. of St. Thomas), MBA (Cornell)Will continue as CEO and Chairman; no compensation changes related to stepping down as President | Board/Committee Role ChangesNot disclosedNot disclosed |
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.